Transforming growth factor (3 (TGF-(3), a polypeptide present in abundant amounts in bone matrix, was examined for its effects on osteoclast formation by using a human bone marrow culture system in which multinucleated cells (MNCs) with osteoclast characteristics form. TGF-.3 strongly inhibited MNC formation at concentrations as low as 1 ng/ml. TGF-fi also completely suppressed the effects of osteotropic factors known to stimulate MNC formation. The inhibitory effect of TGF-13 on osteoclast-like cell formation was more pronounced during the firt week of culture, which corresponds to the period of proliferation of mononuclear osteoclast precursors. To examine whether the inhibitory effects of TGF-(3 on MNC formation could be due to inhibition of the granulocyte/macrophage progenitor cell [colonyforming unit granulocyte/macrophage (CFU-GM)], the probable precursor for MNC, we tested the effects of TGF-13 on CFU-GM formation in presence of a source of colonystimulating factor. Unexpectedly, TGF-,3 at concentrations (0.1-1 ng/ml) that were inhibitory for MNC formation enhanced day 7 CFU-GM colony formation. This increase in CFU-GM colony formation seen in cultures containing TGF-.8 resulted from significantly more granulocytic colonies being formed in the cultures, suggesting that TGF-fi may induce CFU-GM to differentiate preferentially to cells of the granulocytic lineage. Differentiation of CFU-GM to granulocytes rather than osteoclast precursors in response to TGF-.8 would result in inhibition of MNC formation by depleting the precursor pool for MNC. These data suggest that inhibition of osteoclast-like cell formation by TGF-fi may be an important mechanism of control of local bone resorption.
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Transforming growth factor ,B (TGF-f3), a 25-kDa polypeptide with pronounced effects on proliferation and differentiation of a variety of cell lines in vitro (1, 2) , appears certain to be an important regulator of bone metabolism. TGF-3 is present in abundant amounts in the bone matrix (3) , and TGF-P3 activity in bone culture medium is increased by osteotropic hormones that stimulate bone resorption {1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]; parathyroid hormone (PTH)} and decreased by factors that inhibit bone resorption (e.g., calcitonin) (4). TGF-P stimulates the growth and alkaline phosphatase activity of osteoblastic cells (5) (6) (7) (8) , indicating that TGF-P may play an important role in local bone formation. Further, recent data suggest that TGF-,B can also affect osteoclasts. Tashjian et al. (9) demonstrated that TGF-pB stimulates calcium release in neonatal mouse calvaria by means of a prostaglandin-mediated mechanism and suggested that TGF-P may therefore also be a potent stimulator of local bone resorption. However, bone resorption in vivo is not only due to the activity of preformed mature osteoclasts but also to a large degree reflects the result of new osteoclast formation by the proliferation and fusion of osteoclast precursors.
We recently developed a system for examining the formation of osteoclast-like cells from human bone marrow cells in long-term culture (10) (11) (12) . The multinucleated cells (MNCs) that form in these cultures have many characteristics of osteoclasts, including responsiveness to calcitonin and formation ofresorption lacunae on mineralized matrices (13) . By using this culture system, we examined the effects of TGF-/3 on the formation of osteoclast-like cells in vitro and demonstrate in this report that TGF-f3 is a potent inhibitor of osteoclast-like cell formation.
MATERIALS AND METHODS
Collection and Culture of Human Marrow Cells. Bone marrow was aspirated from the posterior iliac crest ofhealthy normal donors. All donors gave informed written consent before bone marrow aspirations. Marrow aspirates were collected in syringes containing 1000 units of preservativefree heparin per ml (Sigma) in alpha minimum essential medium (aMEM) (GIBCO). Marrow mononuclear cells were obtained by centrifugation on Hypaque/Ficoll gradients as described (14) . Mononuclear cells were cultured in aMEM containing 20% horse serum (Flow Laboratories) at 106 cells per ml in 24-well plates (Linbro; Flow Laboratories) (5 x 105 cells per well). All cultures were maintained in a humidified atmosphere of4% C02/air at 37°C for 3 weeks. Cultures were fed weekly by removing 50% of the medium and replacing with an equal volume of fresh medium (unless otherwise noted). Varying concentrations of highly purified TGF-,3 from porcine platelets (>93% pure by NaDodSO4/PAGE and HPLC, R&D Systems, Minneapolis) or from bovine demineralized bone (homogenous by NaDodSO4/PAGE and HPLC, generously provided by S. M. Seyedin) were added to the cultures for the entire 3 weeks ofculture in the presence or absence of 1,25-(OH)2D3 (0.01 ,mM) (generously provided by M. Uskokovic, Hoffmann-LaRoche), TGF-a (0.1 ng/ml) (kindly provided by R. Derynck, Genentech, South San Francisco, CA), recombinant human interleukin la (IL-la) (1 unit/ml) (generously provided by P. Lomedico, HoffmannLaRoche), or human PTH-(1-34) (100 ng/ml) (BaChem, Torrance, CA). Similar results were obtained with either preparation of TGF-p. After 3 weeks of culture, cells were fixed with 5% glutaraldehyde (Sigma) and stained with Wright's stain. Cells containing three or more nuclei were counted as MNCs using an inverted phase-contrast microscope. Results 30 or more cells were counted in situ using an inverted phasecontrast microscope. After counting, the agar cultures were transferred to glass slides, fixed with acetone, and stained with naphthol AS-D chloroacetate esterase (Sigma) to identify granulocytes.
Statistical Analysis. The mean ± SEM was determined for all cultures done in quadruplicate. Results were then analyzed by using a two-way analysis of variance for repeated measures and differences were considered significant for P < 0.05. (Fig. 1 ). TGF-/3 was able to completely suppress the formation of MNC at a concentration as low as 1 ng/ml (Fig. 1) .
RESULTS
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We have previously shown that MNC formation is stimulated by a number of osteotropic factors (10, 11, 14, 17, 18 (Fig. 4) . MNC formation was almost completely inhibited in the cultures that were exposed to TGF-,B only during the first week. Exposure of marrow cells to TGF-,/ for only the first 3 hr of culture significantly inhibited subsequent MNC formation (Fig. 5) . These results suggest that TGF-,3 rapidly inhibits the growth of early MNC precursors and that this inhibition if irreversible. Inhibition of MNC formation was still observed but was much less pronounced when the cultures were exposed to TGF-p during the last week, a time during which little or no proliferation occurs in these cultures (Fig. 4) . These data suggest that We then examined the effects of TGF-P on CFU-GM colony formation because TGF-f3 appeared to act predominantly on a very early stage of MNC formation, and CFU-GM are the probable progenitors for MNCs (19, 20) . Although TGF-,8 strongly inhibited formation of cells with osteoclast characteristics, it had biphasic effects on the proliferation of CFU-GM. We expected that TGF-p would inhibit CFU-GM colony formation. However, when TGF-f3 (0.1-1 ng/ml) was added to CFU-GM cultures containing CSF, CFU-GM colony formation was increased ( ng/ml) that were 10-fold higher than required to inhibit MNC formation. Interestingly, TGF-J3 (0.1 ng/ml) preferentially increased the number of granulocytic colonies formed in CFU-GM cultures, a concentration that inhibited MNC formation. TGF-P did not consistently affect day 14 colony formation. These data suggest that TGF-P was inducing granulocytic differentiation (Fig. 6) have been shown to also stimulate the formation of MNC in this system.
Comparatively less is known about potential factors that inhibit MNC formation. In this report, we demonstrate that TGF-P, a cytokine present in high concentrations in bone, is a potent inhibitor of MNC formation in long-term human marrow cultures. Although TGF-pB strongly inhibited the formation of MNCs, it had no effect on the number of preformed MNCs as analyzed by time-lapse cinemicrography (data not shown) when added during the last 48 hr of the culture nor did it appear to inhibit the growth of fibroblastic cells present in the cultures. MNC formation was inhibited at concentrations of TGF-P as low as 0.1 ng/ml, which are comparable with the minimal effective concentrations of TGF-P in most cell culture systems.
TGF-P also suppressed the effects of all factors known to stimulate MNC formation and completely inhibited increases in MNC formation even at maximally stimulatory concentrations of these factors. TGF-p is stored in abundant amounts in bone matrix and is produced by osteoblastic cells in vitro (8, 32) . Recently, Pfeilschifter and Mundy (4) demonstrated that TGF-,B activity is increased in bone cultures during bone resorption induced by various bone-resorbing factors. This increase in active TGF-P during bone resorption may then induce a variety of direct or indirect responses in the local bone environment. Although the release of prostaglandins in response to TGF-P may in fact increase the activity of preformed mature osteoclasts, TGF-,B may at the same time inhibit the formation of new osteoclasts and thus complete the bone resorption cycle. Supporting this conclusion, TGF-f3 inhibited bone resorption induced by bone-resorbing factors in prolonged cultures (6 days) of fetal rat long bones (33) . Since TGF-,f can have stimulatory effects on proliferation and differentiated functions of osteoblastic cells, it may be a mediator between bone resorption and bone formation by completing the bone resorption cycle and initiating a new cycle of bone formation.
